Dr. Paul Marik FLCCC Cancer Care 2nd Edition 2024/2025 Review: Repurposed Drugs Tier List, Metabolic Protocol & Full Breakdown

By Editorial Team

Important Medical Disclaimer
This article is a review of the publicly available FLCCC monograph Cancer Care: The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer (2nd Edition, Version 2.2, October 2024) by Paul E. Marik, MD. It is not medical advice, does not replace standard oncology care, and is not endorsed as a cure or standalone treatment. The document itself stresses supervision by qualified physicians, shared decision-making, and use primarily as adjunctive therapy. Cancer treatment decisions must be made with your oncologist and healthcare team. Regulatory bodies and mainstream guidelines do not universally endorse many of these off-label approaches.

Available on Amazon

Why This Guide Is Trending in 2026: Repurposed Drugs + Metabolic Cancer Approach

With rising interest in integrative oncology, low-cost adjuncts, and “metabolic” theories of cancer, Dr. Paul Marik’s FLCCC Cancer Care protocol has become a key reference for patients and providers exploring options beyond conventional care.
The 257-page PDF (freely downloadable via FLCCC-affiliated sites) reviews over 1,300 studies and presents a tiered system of repurposed drugs, lifestyle changes, and supportive strategies. It positions itself as adjunctive — aimed at improving quality of life, reducing chemo toxicity, and supporting standard treatments (surgery, chemo, radiation).

Dr. Paul Marik, a highly published critical care physician and FLCCC co-founder, draws from his experience with repurposed protocols (sepsis, COVID) to compile this resource.

Core Thesis: Cancer as a Metabolic Disease?

The guide challenges the dominant “somatic mutation” model and heavily references Dr. Thomas Seyfried’s work on mitochondrial dysfunction and the Warburg effect (cancer cells relying on glucose fermentation).

Key Takeaways from Chapter 2:

  • Defective mitochondria → reliance on glucose + glutamine
  • Standard treatments may inadvertently promote cancer stem cells (CSCs) and metastasis
  • Solution: Starve cancer metabolically while supporting the body

Lifestyle & Metabolic Foundations (Chapters 3–5)The protocol emphasizes foundational changes before or alongside drugs:

  • Ketogenic / “Banting” / Real-Food Diet + Caloric Restriction
  • Intermittent Fasting & Autophagy
  • Exercise (aerobic + resistance)
  • Stress reduction, quality sleep, safe sun exposure (with data suggesting benefits for melanoma survival)
  • Cancer cachexia management

Vitamin D is ranked #1 in Tier 1 — often dosed aggressively (20k–50k IU/day titrated to 55–90 ng/mL with K2 & magnesium).

The Star of the Show: Tiered Repurposed Drugs List (Chapters 6–10)Marik stratifies agents by strength of evidence (mechanistic + clinical + safety):Tier 1 – Strong Recommendation (Core “Cocktail” Candidates)

  1. Vitamin D3
  2. Propranolol (especially peri-operative)
  3. Melatonin (high-dose nighttime)
  4. Metformin
  5. Curcumin (nano-form)
  6. Ivermectin (upgraded in 2nd ed.; 12–18 mg or ~1 mg/kg daily noted)
  7. Mebendazole / Fenbendazole / Albendazole
  8. Green Tea (EGCG)
  9. Omega-3 Fatty Acids
  10. Berberine
  11. Statins (Atorvastatin / Simvastatin)
  12. PDE5 inhibitors (low-dose daily tadalafil/sildenafil)
  13. Disulfiram
  14. Ashwagandha
  15. Itraconazole
  16. Mistletoe
  17. Cimetidine

Tier 2–4 Summary

  • Tier 2: LDN, doxycycline (cycled), spironolactone, etc.
  • Tier 3: IV Vitamin C, artemisinin, cannabinoids, aspirin/NSAIDs (context-specific)
  • Tier 4 (Avoid): Laetrile, shark cartilage, high-dose B vitamins in some settings

Marik’s Favorite Practical Tip: Pre-Operative / Pre-Biopsy Protocol (p70–71)To reduce surgery-induced metastatic risk:

  • Propranolol (40–80 mg BID, titrate to HR 55–70)
  • COX-2 inhibitor (e.g., celecoxib or diclofenac)
  • Cimetidine (optional 200–400 mg BID)
  • Vitamin D boost

Start 7–10 days before procedure. Synergistic potential noted; discuss with anesthesiologist/surgeon.

Evidence Level, Strengths & Important CaveatsStrengths (per document):

  • Dense PubMed citations
  • Actionable dosing notes
  • Strong disclaimers & emphasis on supervision
  • Focus on QoL and toxicity reduction

Limitations & Context:

  • Many interventions remain investigational/off-label for cancer
  • Human RCTs for combinations are limited
  • Mainstream oncology (NCCN, ASCO) does not list most as standard
  • “Turbo cancer” and spike-protein sections are speculative and debated

The author repeatedly states: This is not a cure. Use under medical supervision. Patient autonomy is respected but informed consent and oversight are essential.

Who Is This Guide For?

  • Patients seeking informed discussions with integrative oncologists
  • Providers exploring adjunctive support
  • Individuals focused on prevention & risk reduction

Target Audience Note from Document: Patients should not self-treat. Engage oncologist + integrative provider.

How to Access & Use Responsibly (2026)

  1. Download the full PDF from official FLCCC or affiliated sites (search “FLCCC Cancer Care Marik”).
  2. Share with your care team.
  3. Prioritize Tier 1 + lifestyle.
  4. Monitor labs (especially Vitamin D, glucose, liver/kidney function).
  5. Track with CGM if doing keto/fasting.

Recommended Next Steps:

  • Schedule oncology + integrative consult
  • Validate claims independently
  • Discuss any off-label use thoroughly

Conclusion

Dr. Paul Marik’s Cancer Care 2nd Edition is a detailed, reference-heavy resource that empowers patients to ask better questions about metabolic support, repurposed agents, and lifestyle in cancer care. It respects standard therapies while offering additional tools — always framed as adjunctive and physician-supervised.

Final Reminder: Nothing in this review or the original document replaces professional medical advice. Cancer care is highly individual. Work closely with your doctors.


Have you reviewed the guide? What questions do you have for your oncologist? Comment below (and consult your physician before any changes).
This article is for educational purposes only. All health decisions require licensed medical oversight.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more